Search

Background: Skin melanoma is a malignant tumor originated from skin melanocytes. It is highly malignant and easy to relapse and metastasis. Finding new diagnostic and therapeutic targets has become a hot issue. Accumulating evidence now indicates that thyroid hormone receptor interactor 13 (TRIP13) plays important roles in tumor development. However, its role in melanoma remains unclear.Methods: Bioinformatic analyses were employed to excavate crucial genes in melanoma using several public databases. The expression of TRIP13 was detected by immunohistochemistry. MV3 cell and A2058 cell were steadily transfected with TRIP13 knock-down or overexpression lentiviruses, then the function and potential mechanism of TRIP13 were studied in vitro and in vivo. Co-immunoprecipitation (Co-IP) and mass spectrum were employed to screen out the interacting molecule of TRIP13.Results: Our results showed that TRIP13 was generally upregulated in melanoma tissues and was related to the poor prognosis of melanoma patients. The overexpression of TRIP13 promotes the invasion, migration and EMT transformation of melanoma cells in vitro, and promotes lung metastasis in vivo. Mechanismly, TRIP13 interacts with FLNA, and activates the PI3K/AKT pathway, and then induces melanoma migration, invasion and EMT transformation.Conclusion: Elevated TRIP13 drives tumor progression via the FLNA/PI3K/AKT axis, and TRIP13 is a innovative prognostic molecule and potential target of targeted therapy in melanoma.

Cutaneous melanoma is a high-grade malignant tumor originating from skin melanocytes with high risk of recurrence and metastasis. Further study on the mechanism of melanoma development is urgently needed. Here, we performed a bioinformatic analysis to identify critical genes in melanoma using public datasets in the Gene Expression Omnibus database. Among these differentially expressed genes, thyroid hormone receptor interactor 13 (TRIP13) has been reported to exert an important role in the development of various tumors, while its role in melanoma remains unclear. We selected TRIP13 as a candidate gene for further study. TRIP13 expression in clinical specimens was evaluated by immunohistochemistry, and its association with patient prognosis was analyzed by the Kaplan-Meier method and log-rank test. MV3 and A2058 melanoma cells were transfected with lentiviral vector to overexpress or knockdown TRIP13 expression level, and then, its biological function was studied using a series of in vitro and in vivo assays. RNA sequencing, co-immunoprecipitation, and mass spectrometry were used to identify the underlying mechanism of TRIP13. The results of this study exhibited that TRIP13 expression was upregulated in melanoma tissue compared with normal tissues, and high levels of TRIP13 were closely correlated with poor prognoses of melanoma patients. Elevated TRIP13 promoted the invasion and migration of melanoma cells in vitro and enhanced lung metastasis in vivo, without an influence on tumor growth. Importantly, elevated TRIP13 promoted the epithelial-mesenchymal transition (EMT) of melanoma cells, indicating a higher metastatic potential of these cells. Mechanically, TRIP13 physically interacted with filamin A (FLNA) and then activated the PI3K/AKT pathway to transcriptional activation of EMT-related genes. The present study revealed that TRIP13 is a novel prognostic biomarker and potential therapeutic target for melanoma treatment.